摘要
目的:利用大肠杆菌的基因工程技术,制备重组的人肝再生增强因子(ALR)药物,对于CCl4肝损伤的小鼠模型进行治疗, 评价重组的人肝再生增强因子在肝损伤治疗中的效果和价值. 方法:应用大肠杆菌系统,表达、纯化重组人肝再生增强因子蛋白.利用四氯化碳法制备肝细胞损伤的动物模型,以重组的人肝再生增强因子药物进行治疗,以生理盐水治疗作为对照,比较治疗后血清ALT,AST水平的变化,评价重组的人肝再生增强因子对于肝损伤的治疗作用. 结果:成功制备了重组的人肝再生增强因子药物,纯度在98%以上.成功制备了四氯化碳的小鼠肝损伤模型,经过重组的人肝再生增强因子药物治疗后,血清中ALT,AST水平都有显著的下降(ALT:991 U/L对2 134 U/L,P<0.01; AST:938 U/L对1873 U/L,P<0.01). 结论:重组的人肝再生增强因子药物,有希望成为各种原因引起的肝细胞损伤的治疗药物.
AIM: To explore the therapeutic effects of recombinant human augmenter of liver regeneration (ALR) on CCl4 liver damage of mice. METHODS: The recombinant human ALR was prepared by standard procedure of fermentation and chromatography techniques. Chemical liver damage model of mice was established by CCl4. The mice were divided into two groups: group one was treated by recombinant ALR, 2 mg/kg or 20 μg, 1/12 h, 4 times, and group two was treated by normal saline as control. After treatment, the mice were sacrificed for collecting the blood sample. For evaluation of chemical liver damage, the serum ALT and AST levels were determined by an autobiochemical processor. RESULTS: The CCI4 liver damage model was established. After the treatment with recombinant human ALR, the ALT and AST levels in treated groups were significantly decreased as compared with the group treated with normal saline (ALT: 991 U/L vs 2134 U/L, P<0.01; AST: 938 U/L vs 1873 U/L, P<0.01), indicating the potent therapeutic effects of recombinant human ALR on mice model of chemical damage caused by CCI4. CONCLUSION: Recombinant human ALR is successfully prepared and effective in the treatment of murine CCI4 liver damage.
出处
《世界华人消化杂志》
CAS
2004年第4期859-861,共3页
World Chinese Journal of Digestology
基金
国家自然科学基金攻关项目
No.C03011402
No.C30070689
No.C39970674
No.C30371288军队"九
五"科技攻关项目
No.98D063军队回国留学人员启动基金项目
No.98H038军队"十
五"科技攻关青年基金项目
No.01Q138军队"十
五"科技攻关面上项目
No.01MB135~~
